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Abstract: Ionizing radiation (IR), such as X-rays and gamma (γ)-rays, mediates various
forms of cancer cell death such as apoptosis, necrosis, autophagy, mitotic catastrophe, and
senescence. Among them, apoptosis and mitotic catastrophe are the main mechanisms of IR
action. DNA damage and genomic instability contribute to IR-induced cancer cell death.
Although IR therapy may be curative in a number of cancer types, the resistance of cancer cells to
radiation remains a major therapeutic problem. In this review, we describe the morphological and
molecular aspects of various IR-induced types of cell death. We also discuss cytogenetic variations
representative of IR-induced DNA damage and genomic instability. Most importantly, we focus
on several pathways and their associated marker proteins responsible for cancer resistance and its
therapeutic implications in terms of cancer cell death of various types and characteristics. Finally, we
propose radiation-sensitization strategies, such as the modification of fractionation, inflammation,
and hypoxia and the combined treatment, that can counteract the resistance of tumors to IR.
Keywords: cancer therapy; ionizing radiation (IR); resistance; cell death; DNA damage; prognostic
markers; therapeutic targets
1. Introduction
Radiation therapy is a useful cancer treatment strategy and is a highly cost-effective
single-modality treatment. Radiation therapy uses high doses of radiation to destroy or slow tumor
growth. Ionizing radiation (IR), such as X-rays and gamma (γ)-rays, is usually used for cancer
treatment because it can pass through tissue, break chemical bonds, and remove electrons from atoms
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to become ionized. The resulting ions can kill or cause serious damage to cancer cells. IR does not
kill cancer cells immediately; a significant period of treatment time is required before a large number
of cancer cells start to be killed. IR can also lessen or ease problems and symptoms caused by a
growing tumor. IR may be given before, during, or after surgery or chemotherapies to enhance the
effectiveness of these therapies. IR exposure may be external or internal. External beam radiation
therapies, such as X-rays and γ-rays, involve the targeting of radiation at the cancer in a specific part
of the body. Internal radiation therapies based on the use of electrons, protons, neutrons, carbon ions,
α particles, or β particles are treatments in which a source of radiation, either solid or liquid, is placed
inside the body.
The biological effectiveness of IR in killing cancer cells depends on the type of radiation, total
dose, fractionation rate, and the targeted organs [1]. Although radiotherapy is an effective cancer
treatment, a large portion of patients subsequently experience radioresistance and recurrence of their
cancers. Whereas IR alone can be somewhat effective for the treatment of some cancers such as
larynx cancer, non-small-cell lung cancer, skin cancer, prostate cancer, cervical cancer, head and neck
carcinomas, and lymphomas, it is not effective against other cancers such as breast cancer, bladder
cancer, glioblastoma, soft tissue carcinoma, and advanced non-small-cell lung cancer possibly due
to the intrinsic radioresistance of cancer cells [2]. IR therapy in combination with other modalities
shows promise in the treatment of these radio-resistant cancers. In this review, we will discuss cellular
and molecular mechanisms (signaling pathways) of radioresistance in terms of various types of cell
death and cytogenetic variations. We will also evaluate strategies to overcome radioresistance during
cancer treatment.
2. IR-Induced Cell Death Outcomes
IR therapy, like other types of anticancer treatments, may induce multiple forms of cancer cell
death through a variety of molecular mechanisms. Several modes of cell killing, such as apoptosis,
necrosis, autophagy, mitotic catastrophe, and senescence, occur after exposure to IR (Figure 1).
Int. J. Mol. Sci. 2015, 16, page–page 
2 
resulting ions can kill or cause serious damage to cancer cells. IR does not kill cancer cells 
immediately; a significant period of treatment time is required before a large number of cancer cells 
start to be killed. IR can also lessen or ease problems and symptoms caused by a growing tumor. IR 
may be give  before, duri g, or after surgery or chemothe apies to enhance the effectiveness of th se 
therapies. IR exposure may be external or internal. External beam radiation therapies, such as X-rays 
and γ-rays, involve the targeting of radiation at the cancer in a specific part of the body. Internal 
radiation therapies based on the use of ele trons, protons, neutrons, carbon ions, α particles, or  
β particles are treatments in which a source of radiation, either solid or liquid, is placed inside the body. 
The biological effectiveness of IR in killing cancer cells depends on the type of radiation, total 
dose, fractionation rate, and the targeted organs [1]. Although radiotherapy is an effective ca cer 
treatment, a large portion of patients subsequently experience radioresistance and recurrence of their 
cancers. Whereas IR alone can be somewhat effective for the treatment of some cancers such as larynx 
cancer, non-small-cell lung cancer, skin cancer, prostate cancer, cervical cancer, head and neck 
carcinomas, and lymphomas, it is not effective against other cancers such as breast cancer, bladder 
cancer, glioblastoma, soft tissue carcinoma, and advanced non-small-cell lung cancer possibly due to 
the intrinsic radioresistance of cancer cells [2]. IR therapy in combination with other modalities shows 
promise in the treatment of these radio-resistant cancers. In this review, we will discuss cellular and 
molecular mechanisms (signaling pathways) of radioresistance in terms of various types of cell death 
and cytogenetic variations. We will also evaluate strategies to overcome radioresistance during 
cancer treatment. 
2. IR-Induced Cell Death Outcomes 
IR therapy, like other types of anticancer treatments, may induce multiple forms of cancer cell 
death through a variety of molecular mechanisms. Several modes of cell killing, such as apoptosis, 
necrosis, autophagy, mitotic catastrophe, and senescence, occur after exposure to IR (Figure 1). 
 
Figure 1. Various modes of cancer cell death induced by IR. Apoptosis and mitotic catastrophe are 
major forms of cell death induced by IR. Tumor suppressor proteins such as p53 and tumor 
suppressor lipids such as ceramide promote IR-induced apoptosis. Mitotic catastrophe occurs from 
premature or inappropriate entry of cells into mitosis caused by irradiation. A p53 mutation can make 
the cancer cells susceptible to premature mitosis. Furthermore, the loss of the p53-mediated arm of 
the G2/M checkpoint leads to mitotic catastrophe in cancer cells following exposure to IR. Mitotic 
catastrophe results from aberrant mitosis and eventually causes cell death through apoptosis or 
necrosis. Necrosis is an uncontrolled mode of cell death caused by rapid and severe impairment. Even 
though necrosis is seen less frequently following IR treatment, it does occur after receiving higher 
doses of IR. Autophagy has a dual role in response to cancer cells to IR; it causes cancer cell survival 
or death depending on the specific context (pro-survival or pro-death?). Senescence occurs in cancer 
cells following IR-caused DNA damage and involves p53-mediated cell cycle arrest. Senescent cells 
later die, typically through apoptosis. Stress-induced premature senescence usually occurs in p53-proficient 
cells. Necroptosis is a programmed form of necrosis. Although there is evidence that necroptosis is 
involved in IR-induced cancer cell death, the role of this type of death is a very inchoate area of research 
(novel mechanism of IR-induced cell death?). 
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Figure 1. Various modes of cancer cell death induced by IR. Apopto is an mitotic catastrophe
are major forms of cell death induced by IR. Tumor suppressor proteins such as p53 and tumor
suppressor lipids such as ceramide pro ote IR-induced apoptosis. Mitotic catastrophe occurs from
premature or inappropriate entry of cells into mitosis caused by irradiation. A p53 mutation can
make the cancer cells susceptible to premature mitosis. Furthermore, the loss of the p53-mediated
arm of the G2/M c eckpoint lead to mitotic catastroph in cancer cells following exposure to IR.
Mitotic catastrophe results from aberrant mitosis and eventually causes cell death through apoptosis
or necrosis. Necrosis is an uncontrolled mode of cell death caus d by rapid and severe impairment.
Even though necrosis is seen less frequently following IR treatment, it does occur after receiving
higher doses of IR. Autophagy has a dual role in response to cancer cells to IR; it causes cancer cell
survival or death depending on the specific context (pro-survival or pro-death?). Senescence occurs
in cancer cells following IR-caused DNA damage and involves p53-mediated cell cycle arrest.
Senescent cells later die, typically through apoptosis. Stress-induced premature senescence usually
occurs in p53-proficient cells. Necroptosis is a programmed form of necrosis. Although there is
evidence that necroptosis is involved in IR-induced cancer cell death, the role of this type of death
is a very inchoate area of research (novel mechanism of IR-induced cell death?).
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2.1. Apoptosis
Apoptosis, type I programmed cell death, is a prevalent form of cell death underlying radiation
therapy. Apoptosis is characterized by a series of distinctive morphological features including cell
shrinkage, membrane blebbing, chromatin condensation, DNA fragmentation, and the resultant
formation of apoptotic bodies in which the cellular membrane remains intact. Among a spectrum
of cellular components, DNA is the main target of IR. Damaged DNA triggers signal transduction
pathways involved in cell cycle arrest and apoptosis. DNA damage monitoring and signaling systems
are responsible for cell cycle arrest and checkpoint, and failure of these controls leads to cell death.
Second messengers such as ceramide and free radicals can also mediate IR-induced apoptosis [3].
Various factors are involved in IR-induced apoptosis. Poly(ADP-ribose) polymerase (PARP),
DNA-dependent protein kinase (DNA-PK), p53, and ataxia-telangiectasia-mutated (ATM) play a
role in DNA damage signaling. First, in response to IR-induced DNA damage, especially DNA
strand breaks, PARP detects and binds to DNA strand breaks, resulting in quantitative synthesis
of a poly(ADP-ribose) chain as a signal for the other DNA-repairing enzymes [4]. A transient and
extensive poly(ADP-ribosyl)ation of nuclear proteins occurs early during apoptosis, prior to the
commitment of cell death [5]. Several animal studies indicate that PARP is involved in survival
responses against IR [6–10]. DNA–PK, a nuclear serine–threonine protein kinase, is a member of
the phosphatidylinositol-3 kinase (PI3K) family. The DNA–PK catalytic subunit (DNA–PKcs) forms
foci in response to IR and is upregulated in radiation-resistant tumors or in tumors with poor survival
rates [11,12]. The deficiency of DNA–PKcs increases IR-induced genomic instability [13]. p53 plays
a major role in the cellular response to IR by regulating the transcriptional activation of a number of
downstream target genes, such as p21, GADD45, 14-3-3, bax, and Mdm2. ATM functions upstream
of p53 by phosphorylating Ser15 and stabilizing p53 [14,15]. ATM is involved in the G1/S cell
cycle checkpoint arrest following DNA damage through p53 accumulation and the p53-mediated
induction of p21 and, at the G2 checkpoint, through the phosphorylation of the Chk2 protein [14–18].
ATM/ataxia-telangiectasia-related (ATR)-Chk1/2-CDC25 also participates in the G2 checkpoint.
If cellular damage is too severe to be repaired, the cell undergoes apoptosis. Caspase promotes
the degradation of key cellular components during apoptosis. Interestingly, caspases also cleave
many of the DNA damage repair enzymes to prevent unpromising cellular DNA repair and force
apoptosis. A role for the Rb protein in decision-making at the interface between cell cycle and
apoptosis has been identified [19,20]. The loss of Rb function leads to increased apoptosis largely
by the liberation of the free E2F cell cycle regulator. Hypophosphorylated Rb also triggers apoptosis
and then is cleaved by caspases [21,22]. p53-Dependent apoptosis is an important mechanism by
which tumor growth and progression is inhibited. The transcriptional induction of Bax appears to
be a key feature of this p53-mediated apoptosis [23]. p53 also has a transcription-independent role in
apoptosis through its interaction with Bax, which promotes its activation as well as its insertion into
the mitochondrial membrane [24,25]. The Bax-independent pathway, which involves protein kinase
A, is another mechanism of p53-dependent apoptosis [26]. The roles of p53-independent pathways
in IR-induced apoptosis have also been well documented [27,28]. p53-independent apoptosis is
generally detected late relative to p53-dependent apoptosis [29]. Interestingly, both p53-dependent
and p53-independent apoptotic responses to IR are functionally active in an ATM-independent
fashion [30], indicating that apoptosis does not require increased p53 levels. Mdm2, a p53-specific
E3 ubiquitin ligase, has been shown to be dispensable for IR-induced apoptosis [31].
Ceramide is a potent mediator of the initiation of IR-induced apoptosis. Several tumor
cells resistant to IR-induced apoptosis show defective ceramide signaling [32,33]. A number of
downstream targets for ceramide action against IR, such as ceramide-activated protein kinase
(CAPK), ceramide-activated protein phosphatase (CAPP), PKC, Bad, Akt, and JNK, have been
identified. Pro-apoptotic ceramide signaling has been shown to be mediated by Bad in COS cells [34].
In contrast, PKC activation attenuates ceramide-induced apoptosis in some cancer cell types [35].
Ceramide also suppresses the kinase activity of Akt [36]. Nonetheless, the most important target for
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ceramide action in IR-induced apoptosis seems to be stress-activated protein kinase (SAPK)/c-Jun
N-terminal kinase (JNK). IR utilizes JNK for the amplification of mitochondrial apoptotic death in
cancer cells, and JNK activation is PI3K- or reactive oxygen species (ROS)-dependent. Ceramide also
induces Fas ligand (FasL) expression, and the soluble FasL-activated sphingomyelin pathway has
been demonstrated in IR-induced apoptosis [37].
2.2. Necrosis
Necrotic cells are swollen with nuclear vacuolization, protein denaturation/coagulation, and
random DNA degradation followed by rupture of cellular membranes. Necrosis has historically been
regarded as an uncontrolled, i.e., not genetically regulated, form of cell death. Necrosis is much less
common after IR treatment but does occur. The decision as to whether they will undergo apoptosis
or necrosis after IR exposure seems to be dose-dependent in some cancer cell types. For example,
MG-63 osteosarcoma spheroids die by apoptosis after exposure to 5 Gy IR, while they die by necrosis
after exposure to 30 Gy IR [38], suggesting that a much higher dose of IR triggers necrotic cell death.
2.3. Autophagy
Cells undergoing autophagy, a form of type II programmed cell death, utilize the
autophagic/lysosomal compartment to auto-digest proteins and damaged organelles and to recycle
amino and fatty acids. Autophagy is characterized by sequestration of targeted cytoplasmic
components and organelles from the rest of the cell within a double-membrane vesicle called
the autophagosome. The autophagy pathway is known to be negatively regulated by the
PI3K/Akt/mTOR pathway [39]. Hyperactivation of the autophagy pathway contributes to cell death
but controlled expression has a pro-survival effect.
Autophagy is a genetically regulated stress response seen in some human cancer cell lines
exposed to IR. Compared to apoptosis, autophagic cellular changes are observed after IR in any cell
line. Similar to the continuing debate as to whether the induction of autophagy results in cancer
suppression or progression, the autophagic response of cancer cells to IR reveals somewhat different
effects in terms of radiotherapy. IR treatment induces autophagy in both normal and cancer cells.
IR-induced autophagic cell death has been reported in malignant glioma, breast, and prostate cancer
cells [40]. Some studies suggest that the induction of autophagy might be an advantageous strategy
to increase the anticancer effects of radiotherapy and that chemoagent-induced autophagy provokes
sensitization of cells to irradiation and increases the anticancer effects of radiotherapy [41,42].
In particular, the considerable susceptibility of glioblastoma cells to IR-induced cell death is due to
autophagy rather than to apoptosis. The inhibition of autophagy also tunes the radiosensitization
parameters of malignant glioma cells [43]. On the other hand, autophagy has been found to
contribute to the IR resistance of some cancer cell types [44,45]. These conflicting effects might be
due to the critical role of autophagy for the removal of misfolded/damaged proteins and organelles.
Therefore, autophagy seems to play a double-edged role in the balance between survival and death
processes depending on the tissue type and the expression profiles of genes and proteins that regulate
the apoptosis machinery.
2.4. Mitotic Catastrophe
Mitotic catastrophe or mitotic cell death occurs during aberrant mitosis as a result of aberrant
chromosome segregation, leading to formation of giant cells with an aberrant spindle, de-condensed
chromatin, and multiple micronuclei. This type of cell death is accompanied by the presence of one
or more micronuclei and centrosome overduplication. Together with apoptosis, mitotic catastrophe
accounts for the majority of IR-induced cancer cell death. Mitotic catastrophe occurs due to faulty
mitosis and causes delayed mitotic-linked cell death that takes place via apoptosis or necrosis.
For example, irradiated breast cancer cells die by apoptosis due to delayed cell death associated
with mitotic catastrophe after growth arrest [46]. The FasL, TRAIL (TNF-related apoptosis-inducing
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ligand), and TNF-α death-inducing signaling pathways mediate mitotic catastrophe in these cancer
cells through interactions of their ligands and receptors [47]. In this regard, mitotic catastrophe seems
to be an absolute requirement for late-type cell death and accounts for the late apoptosis observed
after IR exposure.
Interestingly, mitotic catastrophe can be enhanced by p53 deficiency and a weakened G2/M
checkpoint [48,49]. The induction of mitotic catastrophe induced by IR is associated with the
increased expression of cyclin B1 and the kinase activity of Cdc2 [50]. G2/M checkpoint disruptors,
such as caffeine, okadaic acid, or staurosporine, have been shown to promote IR-induced mitotic
catastrophe [51]. Mitotic cell death is also enhanced by inactivating mutations in G2/M checkpoint
genes, such as p21 and 14-3-3-σ [49,52]. These findings suggest that IR-induced cellular damage may
induce the premature entry of cells into mitosis and that mitotic cell death may be a key contributor
to the loss of clonogenic potential in tumor cells and solid tumors exposed to IR, especially those with
p53 deficiency.
2.5. Programmed Necrosis
Recently, a programmed/genetically regulated type of necrosis, necroptosis, was identified.
Necroptosis, also called programmed necrosis or type III programmed cell death, is
caspase-independent and controlled by the receptor-interacting protein 1 and 3 (RIP1/3) kinases [53].
This type of death is a key process in chronic inflammatory diseases, but its role in cancer is largely
unclear. Interestingly, recent studies indicate necroptosis to be a novel mechanism of IR-induced
death of some endocrine cancer cell types, such as thyroid and adrenocortical carcinoma cells [54].
2.6. Senescence
Senescent cells are viable but non-dividing and undergo irreversible cell cycle arrest, stop DNA
synthesis, and become enlarged and flattened with increased granularity. Cellular senescence is a
process that results from multiple mechanisms, including telomere shortening, tumor suppressor
signals such as p53 and p16INK4A/pRb, and DNA damage. These mechanisms prevent
uncontrolled proliferation, and so the cellular senescence can protect cells from developing cancer.
Cellular senescence is triggered by a variety of intrinsic and extrinsic stresses, including IR.
Senescence can occur in cancer cells following IR-induced DNA damage, eventually leading to
cell death mainly by apoptosis. Although p53-independent mechanisms have also been described
in IR-induced senescence [55,56], a genetically regulated response to IR-induced DNA damage is
usually seen in solid tumor-derived cell lines, especially those with wild-type p53 [57]. IR-induced
senescence is a beneficial mechanism through which IR suppresses tumor cell growth. Indeed, the
IR-induced retardation of tumor growth is attributable largely to the induction of senescence, not
apoptosis, in some lung cancer cell types [58]. Given that IR-induced senescence can usually be
achieved at much lower doses of IR than those required to induce apoptosis and that the reduced
dose of IR can help prevent adverse side effects of cancer therapy, other strategies using low-dose IR
for cancer therapy deserve much consideration.
Stress-induced premature senescence (SIPS) may greatly affect the efficacy of radiotherapy, and
the radiation doses achievable using clinical therapeutic regimens can induce SIPS in specific human
tumor cell lines. Irradiated cells undergoing SIPS share many cellular and molecular phenomena
with cells undergoing replicative senescence. Although replicative senescence is programmed at
times when telomeric DNA ends are exposed, SIPS is not programmed but is instead a response
to a given stress [59]. Due to the constitutive activation of telomerase, telomeres are typically stable
and replicative senescence is not usually induced in cancer cells. However, many anticancer agents,
including IR, can induce SIPS in cancer cells while not affecting telomere lengths. These agents
produce double-strand breaks (DSBs), and a common cause of SIPS induction in cancer cells appears
to be irreparable DNA breaks.
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IR-induced DNA damage can occur both directly and indirectly. Actually, the radiation-induced
bystander effect in which irradiated cells transfer damage signals to neighboring unirradiated cancer
cells is a big part of IR-mediated damage. There is emerging evidence that the bystander effect
has a role in the genomic instability and carcinogenesis. [60]. ROS are important factors in the
IR-induced bystander effect [61,62]. Additionally, activated macrophages, nitric oxide (NO), and
various cytokines have been implicated in this phenomenon [63].
Although cellular senescence can exert a strong tumor-suppressive effect by arresting the
growth of cells permanently at risk of malignant transformation, it can also be harmful to
the surrounding microenvironment. The senescence-associated secretory phenotype (SASP) is
responsible for these deleterious effects, promoting the senescence-associated pro-inflammatory
response and resulting tumor progression [64]. Actually, a senescent cell is not a quiescent cell
and adopts an immunogenic phenotype, ultimately leading to the SASP. Senescent cells can exert
potential effects on their microenvironment by triggering SASP factors such as soluble signaling
factors and proteases. Soluble signaling factors, such as interleukins, inflammatory cytokines,
and growth and angiogenic factors, are major components of SASP and can affect neighboring
cells. In addition, senescent cells also secrete some proteases such as matrix metalloproteinases
(MMPs), contributing to tissue remodeling [65]. Moreover, cells undergoing senescence increase
the expression of extracellular insoluble molecules such as fibronectin [66]. Fibronectin exerts
multiple effects on biological processes, including cell adhesion, survival, growth, differentiation,
and migration. Additionally, senescent cells may also exert effects on the tissue microenvironment
through the secretion of molecules other than proteins. Together, these SASP components secreted
from senescent cells can modify neighboring cells and microenvironment by altering cell-surface
receptor signal transduction.
However, SASP is also known to contribute senescence reinforcement in damaged cells. In fact,
even a low dose of IR induces SIPS, and these premature cells overexpress several SASP proteins.
Some studies suggest that the IR-induced increase in secretory inflammatory signals might contribute
to the development of IR-induced damage and premature senescence [67]. Therefore, the secretory
program triggered by IR-induced DNA damage can be a critical determinant of the response of
tumors to radiotherapy (the sensitivity or resistance to IR) by modifying the tumor microenvironment
and its interaction with tumor cells.
3. Genomic Instability and Cytogenetic Alterations Induced by IR
One of the potent ways in which IR works is through damaging the DNA of exposed tumor
tissue, leading to cell death. IR triggers DNA damage in cells both directly and indirectly.
The direct effect occurs when the radiation interacts with the DNA molecule itself, while indirect
DNA damage is caused by radiolytic products like free radicals that are highly reactive due to
the presence of unpaired electrons. IR simultaneously produces various types of lesions, such as
base modifications, alkali-labile sites, DNA–DNA intra- and inter-strand crosslinks, DNA–protein
crosslinks, single-strand breaks (SSBs), and double-strand breaks (DSBs). These lesions are efficiently
detected and repaired by different mechanisms (Figure 2).
3.1. Base Damage
IR irradiates and exerts damaging action on free bases, nucleosides, and nucleotides in DNA.
IR-induced modifications of bases affect the DNA structure by distorting the DNA double helix.
In general, the damaged bases have a minor role in IR-induced cytotoxicity and can be repaired
easily through base excision repair (BER) or nucleotide excision repair (NER), with the help of an
undamaged template strand and repair enzymes. DNA glycosylases excise the damaged base to
generate abasic (AP) sites which are further processed by an AP endonuclease. Although polymerase
β is important in the repair of oxidized bases in in vitro studies, IR-induced base damage is repaired
primarily by the DNA polymerase β-independent long-patch subpathway [68].
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Figure 2. Different types of repairs fix different types of DNA damage caused by IR. Through direct 
effects involving the deposition of ionizing energy in the DNA itself or indirect effects involving the 
absorption of ionizing energy by water, leading to the production of water radicals and their 
subsequent reaction with DNA, IR induces several types of damage to DNA. While IR induces a 
variety of DNA damages, the DNA DSB is a main lesion responsible for the aimed cancer-cell killing 
in radiotherapy. DNA repair machineries in response to different types of IR-triggered DNA damage 
are illustrated. 
3.2. DNA SSBs 
High-energy IR can disrupt the sugar phosphate backbone, causing either SSBs or DSBs. SSBs 
are discontinuities or nicks in the deoxyribose backbone of one of the DNA double helixes and are 
usually accompanied by the loss of a single nucleotide at the site of the break. SSBs arise either directly 
from damage on the deoxyribose or indirectly as normal intermediates of DNA BER. SSB repair is 
performed by the serial actions of PARP, polynucleotide kinase (PNK), DNA polymerase, and DNA 
ligase. XRCC1 also plays an important role in SSB repair by stimulating the activity of PNK at 
damaged DNA termini [69]. DNA polymerase fills the gap and the remaining nick is then sealed by 
DNA ligase. Both PARP and XRCC1 mutant cells exhibit an enhanced sensitivity to IR [70,71]. Although 
DNA polymerase β does not seem to affect radioresistance, it has been shown to contribute to SSB 
repair through its interaction with XRCC1 [72]. 
3.3. DNA DSBs 
DSBs are breaks in the phosphodiester backbone of both strands of the DNA separated by  
~10 base pairs or fewer. Unlike SSBs, DSBs are highly toxic, irreparable, and more responsible for a 
great part of the killing of cancer cells as well as surrounding normal cells because they lead to the 
large-scale loss or rearrangement of genetic materials during replication and mitosis. Hence, DSBs 
are the most deleterious lesion produced by IR. 
In mammalian cells, DSBs are repaired primarily by the following two mechanisms: non-homologous 
end-joining (NHEJ) and homologous recombination (HR). The balance between NHEJ and HR is 
highly regulated, and the choice between these two mechanisms is affected by the chemical 
complexity of the breaks, chromatin conformation, and the cell cycle. 
Simple and primary DSBs are likely repaired by NHEJ. NHEJ starts with the binding of the 
Ku70/Ku80 heterodimer to the DSB termini, followed by the recruitment and activation of DNA–PK. 
Incompatible ends are trimmed by nucleases. The ligation complex, which consists of DNA ligase IV, 
X-ray cross-complementation group 4 (XRCC4), and Xrcc4 like factor (XLF), seals the break. NHEJ is 
the primary method of repairing breaks due to IR because DSBs produced in euchromatin are 
repaired mainly by NHEJ throughout the cell cycle [73,74]. HR provides greater repair fidelity than 
NHEJ [75]. 
DSBs in heterochromatin are processed mainly by HR mechanisms [76]. In the HR pathway, the 
MRN (Mre11/RAD50/Nbs1) complex recognizes and binds to DSB ends and subsequently recruits 
and activates ATM to initiate HR. CtIP (CtBP-interacting protein) is also critical for HR-mediated DSB 
repair. MRN–CtIP–complex is important for facilitating the DNA resection at the DSB to generate  
3’-single-stranded DNA (ssDNA). The ssDNA tail is first coated by replication protein A (RPA), 
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effects involving the deposition of ionizing energy in the DNA itself or indirect effects involving
the absorption of ionizing energy by water, leading to the production of water radicals and their
subsequent reaction with DNA, IR induces several types of damage to DNA. While IR induces a
variety of DNA damages, the DNA DSB is a main lesion responsible for the aimed cancer-cell killing
in radiotherapy. DNA repair machineries in response to different types of IR-triggered DNA damage
are illustrated.
3.2. DNA SSBs
High-energy IR can disrupt the sugar phosphate backbone, causing either SSBs or DSBs.
SSBs are discontinuities or nicks in the deoxyribose backbone of one of the DNA double helixes
and are usually accompanied by the loss of a single nucleotide at the site of the break. SSBs arise
either directly from damage on the deoxyribose or indirectly as normal intermediates of DNA BER.
SSB repair is performed by the serial actions of PARP, polynucleotide kinase (PNK), DNA polymerase,
and DNA ligase. XRCC1 also plays an important role in SSB repair by stimulating the activity of PNK
at damaged DNA termini [69]. DNA polymerase fills the gap and the remaining nick is then sealed
by DNA ligase. Both PARP and XRCC1 mutant cells exhibit an enhanced sensitivity to IR [70,71].
Although DNA polymerase β does not seem to affect radioresistance, it has been shown to contribute
to SSB repair through its interaction with XRCC1 [72].
3.3. DNA DSBs
DSBs are breaks in the phosphodiester backbone of both strands of the DNA separated by
~10 base pairs or fewer. Unlike SSBs, DSBs are highly toxic, irreparable, and more responsible for
a great part of the killing of cancer cells as well as surrounding normal cells because they lead to the
large-scale loss or rearrangement of genetic materials during replication and mitosis. Hence, DSBs
are the most deleterious lesion produced by IR.
In mammalian cells, DSBs are repaired primarily by the following two mechanisms:
non-homologous end-joining (NHEJ) and homologous recombination (HR). The balance between
NHEJ and HR is highly regulated, and the choice between these two mechanisms is affected by the
chemical complexity of the breaks, chromatin conformation, and the cell cycle.
Simple and primary DSBs are likely repaired by NHEJ. NHEJ starts with the binding of the
Ku70/Ku80 heterodimer to the DSB termini, followed by the recruitment and activation of DNA–PK.
Incompatible ends are trimmed by nucleases. The ligation complex, which consists of DNA ligase IV,
X-ray cross-complementation group 4 (XRCC4), and Xrcc4 like factor (XLF), seals the break. NHEJ is
the primary method of repairing breaks due to IR because DSBs produced in euchromatin are repaired
mainly by NHEJ throughout the cell cycle [73,74]. HR provides greater repair fidelity than NHEJ [75].
DSBs in heterochromatin are processed mainly by HR mechanisms [76]. In the HR pathway, the
MRN (Mre11/RAD50/Nbs1) complex recognizes and binds to DSB ends and subsequently recruits
and activates ATM to initiate HR. CtIP (CtBP-interacting protein) is also critical for HR-mediated
DSB repair. MRN–CtIP–complex is important for facilitating the DNA resection at the DSB to
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generate 3’-single-stranded DNA (ssDNA). The ssDNA tail is first coated by replication protein
A (RPA), which is subsequently replaced by Rad51 to form a RAD51–ssDNA nucleofilament.
This nucleofilament searches for the homologous sequence elsewhere in the genome and mediates
DNA strand invasion. RAD51-mediated DNA strand invasion forming a displacement loop (D-loop)
can establish a replication fork with a Holiday junction. HR is mostly involved in the repair of
clustered and secondary DSBs that occur later after IR during S and G2 phases when the replication
fork collapses at unresolved single-strand DNA lesions and the sister chromatids are available to
allow recombination processing.
In addition to the formation of radiation-induced prompt DSBs, replication-mediated DSBs are
also formed after ionizing radiation [77]. Replication-mediated DSBs, which are chemically distinct
from prompt DSBs, are formed when unrepaired non-DSB clustered damage sites meet replication
forks to produce replication-mediated DSBs, which require HR for their repair.
3.4. DNA–Protein Crosslinks
DNA–protein crosslinks are covalent bonds and biologically active nucleoprotein complexes
formed between one strand of DNA and proteins. The crosslinking of DNA to nuclear proteins can
impair many cellular processes such as DNA replication, transcription, and repair. DNA–protein
crosslinks are induced linearly with γ-rays doses at a frequency of ~150 Gy [78]. At high doses of
more than 200 Gy, the number of crosslinks approaches a plateau value corresponding to the number
of sites at which DNA attaches to the nuclear matrix [79]. Free-radical formation is believed to be
primarily responsible for the production of DNA–protein crosslinks. The role of this crosslinking in
response to IR is generally not well defined, although some evidence suggests that it does not play a
major role in IR-induced cell killing [80].
4. Resistance Pathway
IR is effective for the treatment of many cancer types; however, in some patients a few tumors
become resistant to radiation, making radiotherapy less effective. Resistance to radiation therapy
remains a major clinical problem, leading to a poor outcome for cancer patients. Several specific
signaling pathways contribute to cellular resistance against IR (Figure 3). Below we review the
molecular signaling pathways associated with resistance to IR.
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4.1. Adaptive Pathway
The recent development of precise radiation delivery techniques increases the efficacy of
radiotherapy for cancer treatment. However, when malignant tumor cells recur after radiation
treatment, they may acquire a resistance to additional radiotherapy. The use of low-dose IR
for radioadaptive protection is known to be efficacious because cells exposed earlier to a lower
inducing radiation dose have reduced sensitivity to a higher challenge dose. The exposure of
mammalian cells to low-dose IR results in beneficial effects in terms of maintenance of genomic
integrity and ability to repair damaged DNA [81,82]. Mitochondria are key sources of ROS as
by-products of aerobic metabolism, and induced ROS production is counteracted by mitochondrial
enzymatic antioxidant systems. Given that IR treatment significantly upregulates the most powerful
antioxidant, manganese-containing superoxide dismutase (Mn–SOD) [83], and that the low-dose
IR-induced adaptive response is linked to alterations in the mitochondrial protein import [84],
mitochondrial signaling (particularly during apoptosis) seems to be implicated in the adaptive
response to IR. As described below, several pro-survival signaling pathways are involved in
radioadaptive resistance.
Cyclins bind and activate cyclin-dependent kinases (CDKs), important regulators of the cell
cycle. A fluctuation in cyclin expression and the resultant oscillation in CDK activity drives
the mitosis. Induced cyclin D1 interacts with CDK4 or CDK6 and activates its kinase activity,
which is required for G1/S cell cycle progression [85]. Cyclin D1–CDK4/6 complex has also been
shown to phosphorylates and it inactivates tumor suppressor protein Rb whose inhibition induces
the expression of several genes involved in S phase progression [86]. This protein is frequently
overexpressed in a variety of tumors and contributes to tumor therapy resistance and a poor
prognosis in cancer patients [87–89]. The enforced translocation of cyclin D1–CDK4/6 from cytosol
to nucleus triggers apoptosis [90]. Cyclin D1 also has a function in low-dose IR-induced adaptive
radioresistance [91]. Contrary to high-dose IR (e.g., 5-Gy ã-ray) triggering 14-3-3ζ-mediated cyclin
D1 nuclear import, low-dose IR (e.g., 10-cGy X-ray) causes a dissociation of the cyclin D1/14-3-3ζ
complex and cytosolic accumulation of cyclin D1, indicating that increased cytosolic cyclin D1
expression is required for the low-dose IR-induced adaptive response. Free and increased cyclin
D1 protects cells from high-dose IR-induced apoptosis by binding to and inhibiting the action of Bax,
suggesting that low-dose IR-induced accumulation of cytosolic cyclin D1 protein plays an important
role in suppressing mitochondrial apoptosis in the IR-induced adaptive resistance.
The Rel/NF-kappaB (NF-κB) protein comprises a family of highly regulated dimeric
transcription factors that are implicated in the control of diverse cellular functions, such as the stress
response, inflammation, cellular growth, and programmed cell death. The high basal NF-κB activity
confers the resistance of certain cancers to chemotherapy and radiotherapy [92,93]. Several studies
show that the fractional IR triggers NF-κB activation and clonogenic survival [94], indicating that
the activation of NF-κB is required for the induction of radioadaptive resistance following exposure
to a radiation dose equivalent to that used medically for diagnostic purposes. The IR-mediated
induction of cytokines (e.g., TNF-α), MEK/ERK pathways, and ATM is involved in NF-κB activation.
IR treatment also induces a variety of NF-κB target proteins that may be responsible for tumor
radioresistance. For example, cyclin B1 is responsible for radioadaptive resistance induced by
chronic exposure to fractionated IR [95]. A recent study also indicates that the non-canonical NF-κB
pathway component RelB regulates Mn-SOD and the resistance to IR of prostate cancer cells [96],
suggesting that, as well as the canonical pathway, the non-canonical pathway is important for
radiation resistance.
Survivin, a member of the inhibitor of apoptosis (IAP) family, functions to prevent caspase
activation and inhibit apoptosis. Survivin has also been implicated in many adaptive responses
to cellular stress, acting as an important factor in tumor cell resistance [97]. The low-dose IR
induces the elevation of survivin levels and the reduction of apoptosis [97]. The knockdown of
survivin induces the loss of the adaptive response, and the survivin-mediated adaptive response
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has the potential to affect outcomes if induced regularly throughout a course of radiation therapy.
A small increase in survival, each day of treatment, induced through exposure to a very low dose
of radiation can lead to persistent induction and maintenance of the survivin-mediated adaptive
response. Because survivin is overexpressed in malignant cells and can be elevated by both high and
very low doses of IR, it is recognized as an important risk factor associated with adverse outcomes in
radiotherapy. The survivin-mediated radioadaptive response is dependent upon the ability of cells
to activate NF-κB [98].
ROS, which seem to be transiently produced in response to IR, contribute importantly to
the cytotoxic effect of IR. Free radicals produced upon IR treatment are the primary source of
ROS and reactive nitrogen species (RNS). However, ROS also participate in the cellular signaling
processes that lead to an adaptive response that reduces the effectiveness of radiation therapy [99].
ROS generated by IR not only serve to trigger oxidative stress but also contribute to TRAF-mediated
NF-κB activation. The NF-κB-mediated anti-apoptotic gene transcription provides enhanced cell
survival upon re-exposure of irradiated cells to IR. Antioxidant defense mechanisms, including
various antioxidant enzymes, are regulated by NF-κB and prevent tissue damage and ROS-related
complications. These antioxidant enzymes, including SOD, catalase, and glutathione peroxidase,
have enzymatic ROS-scavenging systems. Peroxiredoxins (Prxs), members of a family of peroxidases,
play crucial roles in maintaining redox balance, thereby reducing peroxide-induced redox damage.
Peroxiredoxin II (PrxII) is induced by oxidative stress and plays an important role in antioxidant
defense by modulating ROS/RNS regulating networks [100,101]. PrxII is significantly upregulated
in radioresistant cancer cells, and this upregulation is related to the radioresistant phenotype [102],
suggesting that Prx confers radioresistance by eliminating the IR-induced ROS. Therefore, PrxII is
likely one of the key players in the protection against oxidative stimuli and in the increased resistance
of cancer cells to IR.
4.2. DNA Damage Repair Pathway
Although IR is by far the most common therapy for glioblastoma, the most aggressive brain
cancer, standard radiotherapy has only limited effectiveness due to its radioresistance. Glioma stem
cells confer radioresistance by eliciting DNA damage checkpoint signal transduction and a highly
efficient DNA repair system. Deficiency in DNA repair pathways may alter the IR resistance
of glioblastomas.
DNA-dependent protein kinase (DNA–PK) plays a central role in the repair of IR-induced
DSBs [103], and its deficiency has been implicated in IR sensitivity in glioblastoma cells [104].
DNA-PK, a nuclear serine/threonine protein kinase, phosphorylates several transcription factors
and is responsible for DNA repair, cell cycle arrest, apoptosis, and so on. It is a trimeric enzyme
consisting of a large catalytic subunit (DNA–PKcs) and heterodimer DNA-binding complex, which
comprises 70 (Ku70) and 80 (Ku80) kDa subunits. When a DSB is introduced, the Ku heterodimer
binds to the DSB ends, and it then recruits DNA–PKcs. Although the exact mechanism by which the
Ku/DNA complex activates the kinase activity of DNA–PKcs is unclear, the conformational change in
DNA–PKcs that occurs upon association with the Ku/DNA complex may account for the activation
of kinase activity. Because the expression of a kinase-dead mutant of DNA-PKcs fails to confer the
radioresistant phenotype in a DNA–PKcs-deficient mammalian cell line [103], the kinase activity
of DNA–PK is believed to be needed for DNA repair. In particular, DNA–PK plays a key role in
NHEJ and has the structural and regulatory functions of being activated by DSBs and mediating DSB
end-joining [105].
In humans, RAD51 acts as a key facilitator of the HR DSB repair pathway [106,107].
Its overexpression is observed in many tumors and is linked to increased radioresistance and poor
outcomes [108]. RAD51-related radioresistance is likely to be affected by p53 status because p53
negatively regulates RAD51 expression [108] and is the most frequently mutated gene in human
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cancers. Several reports suggest that HR and high levels of RAD51 are positively correlated and
that RAD51 overexpression increases HR [106–108].
PARP is intimately involved in the early stages of DNA damage responses, together with
other DNA damage sensors, such as DNA–PK, ATM, and ATR. It recognizes and binds to DNA
strand breaks [109] and transfers ADP ribose groups from NAD+ to target nuclear proteins, mainly
itself [110]. Upon the PAR polymer formations, the poly(ADP-ribose) glycohydrolase (PARG) enzyme
catalyzes the hydrolysis of PAR, permitting access of the DNA repair machinery to the lesion [4,111].
PARP has been shown to play a role in both SSB and DSB repair pathways. PARP is a central regulator
in BER and participates in SSB repair. Although the mechanisms by which PARP contributes to NHEJ
and HR are not as well defined as in BER and SSB repair, PARP has been shown to interact with
DSB repair proteins such as NBS1, Mre11, Ku80, DNA–PKcs, and ATM [112–115]. Given that IR
significantly induces PARP and levels of PARP are higher in tumors [116,117], PARP might be useful
therapeutic target in radiotherapy. The BRCA1 tumor suppressor protein repairs damaged DNA and,
therefore, ensures the stability of the cell’s genetic materials. BRCA1 relocates to DNA damage sites,
colocalizes with RAD51, and forms nuclear RAD51 foci in response to IR-induced DNA DSBs [118].
BRCA1 participates in both NHEJ and HR repair process. BRCA1 binds to the MRN complex [119]
and suppresses the exonuclease activity of MRE11 [120]. It is also involved in ATM-mediated
phosphorylation of NBS1 after DNA damage [121]. The formation of BRCA1-PALB2-BRCA2 complex
is essential for RAD51-dependent HR repair [122,123]. Interestingly, potent PARP inhibitors have
cytotoxic effects on BRCA1- and BRCA2-deficient cells, including tumor cells [124,125], suggesting
that PARP inhibitors can be promising therapeutic agents for cancer with disruption of BRCA genes.
One of the apical activators of DNA damage response is the ATM kinase. Mutation in
this gene is associated with ataxia telangiectasia, an autosomal recessive disorder. ATM may
regulate radiosensitivity in that ataxia telangiectasia patients are hypersensitive to radiotherapy.
The radiosensitizing effects of nonspecific inhibitors, such as caffeine, and highly selective ATM
inhibitors, such as KU55933 and CP466722, have also been documented [126].
While IR induces a variety of DNA lesions, including base damage and SSBs, DSBs are
widely considered to be the main contributors to IR-induced cell killing through the induction
of chromosomal aberrations. Therefore, the pathways for the processing of DSB represent a
major mechanism of radiation resistance in tumor cells. The two different cellular pathways
contribute to DSB repair and genome integrity in higher eukaryotes: NHEJ, which can be subdivided
into DNA–PK-dependent NHEJ, alternative/backup NHEJ, and HR. Normal and cancer cells
utilize the DNA–PK-dependent NHEJ pathway extensively to remove DSBs from their genome.
Alternative/backup NHEJs, like DNA–PK-dependent NHEJ, are active in all four stages of the
cell cycle, but their activity is significantly enhanced during S and G2, probably because the
DNA end-resection step occurs primarily in these cell cycle phases [127]. The HR pathway
requires sequence information present on intact DNA strands to remove DSBs and to faithfully
restore genomic integrity. One form of HR utilizes the sister chromatid as the information
donor and is therefore restricted to the late S and G2 phases. Therefore, HR, like alternative
NHEJ, regulates DNA damage repair in a cell cycle-dependent manner. The HR pathway is
aberrantly expressed in many tumors, and tumor radioresistance, poor prognosis, and increased
HR activity are correlated [127], indicating that this pathway is an ideal target for therapeutic
intervention in radiotherapy. Therefore, targeting the DNA damage checkpoint response and
repair pathways in cancer cells (or cancer stem cells) may offer potential therapeutic advantages to
overcome radioresistance.
4.3. Adhesion Pathway
Cell adhesion influences cell survival, preventing cell death through multiple mechanisms.
The adhesion of cells to the extracellular matrix (ECM) as well as to other cells can regulate various
cellular processes, and has been implicated in the development of radioresistance. Especially, cell
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adhesion to ECM protein fibronectin modulates radiation-induced G2/M arrest and increases
resistance to IR. Adhesion, migration, and invasion of the surrounding ECM by cancer cells
are mediated predominantly by cell surface receptors, including integrins and other associated
adhesion molecules.
Integrins are transmembrane receptors that are the bridges for the interactions between cell and
cell or cell and ECM, and are involved in cell adhesion in many cellular processes, including immune
defense, embryogenesis, wound healing, and metastasis. Resistance to radiotherapy is modulated
by the interaction between the ECM and integrins. Integrins modulate the cellular response to
IR and decrease IR-induced cancer cell death [128,129]. Some studies indicate that integrins and
type 1 insulin-like growth factor receptor (IGF-1R) may play a concerted role in the radioresistance
of cancer cells [130–133]. Integrins are heterodimeric proteins comprising á and β subunits, and
at least 18 á and 8 β subunits have been described in mammals. Among the various integrin
units, β1 integrins are associated with very late antigen receptors and conjoin with the á3 subunit
to create the á3β1 complex, which reacts to netrin-1 and reelin. β1 integrins, whose expression
is tightly regulated by IGF-1R, are believed to mediate resistance to IR through inhibition of JNK
activation [133]. Likewise, β1 downregulation or inhibition plays an important role in increasing
cancer cell sensitivity to radiotherapy [133], implying a therapeutic strategy. However, the role of JNK
activation in radioresistance is somewhat controversial given that β1-mediated signaling through the
FAK/cortactin/JNK pathway was recently reported to be associated with radioresistance in head and
neck squamous cell carcinoma [134]. Integrin cleavage can also be a sensitizing factor to IR in prostate
cancer [135].
Integrins regulate cellular functions through the signaling molecules colocalized in the focal
adhesion complex. Focal adhesions and large macromolecular assemblies form structural links
between the ECM and the actin cytoskeleton and are important sites for regulatory signal
transduction. Focal adhesion kinase (FAK) is a cytoplasmic focal complex-associated tyrosine
kinase that is elevated in a variety of human cancers [136]. It triggers the expression of various
antiapoptotic proteins. Compared to HL-60 cells, HL-60/FAK cells are highly resistant to IR-induced
apoptosis through the activation of the PI3K-Akt pathway and the induction of IAP proteins such as
c-IAP-2 and XIAP [137]. FAK overexpression usually prevents IR-induced mitochondria-dependent
apoptosis. Paxillin, one of the main focal adhesion proteins of integrin signaling, is a multi-domain
adaptor protein that is localized in the focal adhesion complex [138]. To facilitate adhesion,
paxillin is phosphorylated and activated by FAK [139]. Mechanistically, interactions of the β1
integrin with Akt, p130Cas, and paxillin contribute to radiation resistance [140]. Furthermore, the
interconnected cytoskeletal network involving ECM, integrins, cytoskeleton, nuclear matrix, and
chromatin organization may affect the cancer cell responses to various anticancer agents, including IR.
4.4. Inflammation Pathway
The immune system plays a pivotal role in controlling tumor development, suppression, or
progression. Radiotherapy can modulate antitumor immune responses, modifying the tumor and
its microenvironment through the activation of cytokine cascades. Cytokines, such as TNF-α, IL-1α,
IL-1β, IL-6, and TGF-β, are produced by tumor cells and tumor-infiltrating lymphocytes and can
greatly influence cellular radiosensitivity and the onset of tissue complications. For example,
IL-6 upregulation is positively linked to radiation resistance while its inhibition enhances the
radiation sensitivity of prostate cancer cells [141]. The balance between proinflammatory and
anti-inflammatory cytokines is critical in determining the outcome of, and adverse reactions and
resistance to, radiation treatment. Cytokines can influence the dose-dependent IR response by their
pleiotropic effects, modulating inflammation, invasiveness, and fibrosis. Many factors, including
radiation dose, tissue type, and the intrinsic characteristics of tumor cells, can cause the local response
to be a pro- or anti-tumor effect after radiation exposure. Total dose and number of fraction applied
are likely to be key determinants in the immune response after radiation exposure. A large single dose
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of irradiation may produce a more potent immune response than low-dose fractionated radiation.
An inflammatory IR response can also favor the invasion of cancer cells, providing a favorable
environment for tumor promotion and metastasis. The ability of radiation to increase invasiveness
has been reported for pancreatic, rectal, and colon cancer cells [142]. Both IL-8 and IL-6 are involved in
the IR inflammatory response and enhance cancer cell invasiveness [142,143]. In addition, IR-induced
IL-1β expression can also favor cancer cell invasion [142]. Moreover, some preclinical models suggest
that radiation-activated TGF-β can contribute to metastasis, inducing the appearance of mesenchymal
characteristics [144].
Radiation-induced transcription factors, such as the NF-κB family and signal transducer
and activator of transcription-3 (STAT3), are linked to radioresistance due to the production of
a variety of proteins including cyclin D1, VEGF, MMP, and proinflammatory cytokines [145].
Whereas the induced expression of these target genes in response to radiotherapy is responsible for
the inducible and/or adaptive radioresistance, constitutively activated NF-κB or STAT3 contributes
to intrinsic radioresistance [145]. Upregulation of NF-κB by TNF exposure confers increased
radiation resistance to cancer cells. The STAT3-mediated radioresistant phenotype is the result of
multiple mechanisms in combination with radiation-induced activation of the Janus-activated kinase
(JAK)-STAT pathway [145–147]. Erythropoietin, which plays an important role in the neoplastic
transformation and malignant phenotype progression observed in malignancy, induces resistance
to IR in human cancer cells in a JAK2-dependent manner [148].
Radiation is also known to induce inflammation through cyclooxygenase-2 (Cox-2) [142]. Cox is
necessary for the conversion of arachidonic acid to the family of prostaglandins and its activity in
cancer can be directly stimulated by NF-κB after radiation exposure or indirectly by the activity
of several cytokines. Cox-2 is overexpressed in various types of cancer [142]. In particular,
Cox-2 upregulation is associated with a higher tumor grade and distant metastases in breast
cancers [149]. This protein has assumed an important role as a therapeutic target for anticancer and
anti-inflammatory therapies. In particular, Cox-2-derived prostaglandins are thought to protect cells
from radiation-induced damage, contributing to tumor growth and resistance to radiation therapy.
Cox-2 activation via the PI3K/AKt pathway can also induce resistance to radiation in human cancer
cells [150]. Collectively, the use of specific inhibitors or drugs that manipulate cytokine pathways
should be encouraged to improve radiation therapy because TNF-α, IL-1β, IL-8, IL-6, or TGF-β
can influence the response to IR by inducing inflammation, cancer cell invasiveness, and fibrosis
in irradiated tissues.
4.5. Developmental Pathway
Although IR represents the optimum non-invasive therapy for many cancers with benefits in
terms of overall survival, it may also cause therapy failure due to the presence of cancer stem cells.
Cancer stem cells account for only a small part of the bulk tumor, but are the cardinal reason for
therapeutic resistance. Developmental pathways, including the Hedgehog, Wnt/β-catenin, and
Notch pathways, have long been postulated to play an important role in maintaining cancer stem
cells and thereby the cancer itself. Self-renewal pathways are known to contribute to cancer stem cell
resistance to IR. IR treatment commonly induces stemness in cancer cells.
The Hedgehog signaling pathway plays a crucial role in development and patterning during
mammalian embryogenesis [151–153]. The binding of the Hedgehog ligand to the Patched receptor
regulates target genes that are involved in many cellular functions including survival, proliferation,
and metastasis. This pathway also affects the maintenance of the cancer stem cell population by
exerting pro-proliferative effects in cancer stem cell/stem cell-like populations in many types of
cancer [154–156]. Moreover, Hedgehog pathway signaling is upregulated in various cancers [157–159]
and is associated with the epithelial-to-mesenchymal transition (EMT) [160,161]. Given that stem
cells confer resistance to chemotherapy and radiotherapy, the Hedgehog pathway may have a role in
radiotherapy. For example, this pathway modulates radiation therapy resistance in head and neck
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cancer [162]. The combination of IR and the Hedgehog pathway inhibitor cyclopamine demonstrates
improved tumor cell control both in vitro and in vivo [162], suggesting an additive benefit over either
therapy alone.
In fractionated IR treatment, a small amount of radiation is delivered to the patient at regular
intervals over a prolonged period. However, the first fraction of radiation can stimulate the migratory
and invasive capacities of the tumor cells, resulting in tumor relapse and metastasis [163,164].
IR treatment can activate multiple signaling pathways in tumor cells, which modulate cellular
functions and induce the secretion of cytokines and growth factors, promoting the migration and
invasion of various types of cancer cells, including glioblastoma, the most common and lethal
brain cancer [163]. The Wnt/β-catenin pathway, especially the canonical pathway, is believed to
be important in maintaining the stemness of cancer stem cells and in promoting cellular invasiveness
through the regulation of the EMT in many cancers [165]. The Wnt/β-catenin pathway mediates the
radioresistance of glioblastoma by promoting invasion [166,167], raising the interesting possibility
that invasiveness and radioresistance are phenotypes associated with Wnt/β-catenin signaling.
Therefore, targeting radiation-induced invasion can be a promising therapeutic modality for the
treatment of cancer.
The Notch signaling pathway plays crucial roles in the control of cell–cell communication, cell
fate, and pattern formation [168,169]. The Notch pathway is also involved in stem cell proliferation,
differentiation, and apoptosis [170]. The role of the Notch pathway can be either oncogenic or
tumor-suppressive in that it functions as an oncoprotein in most human cancers, including lung,
colon, cervical, prostate, pancreatic, and head and neck cancer, but acts as a tumor suppressor in skin
cancer, hepatoma, and small-cell lung cancer (SCLC) [171–173]. This pathway is often overactivated
in a variety of cancers [174], and is believed to be a candidate target for therapies designed to
eliminate cancer stem cells. Notch activity in established breast cancer cells is increased in response
to radiotherapy [175]. High Notch activity is correlated with radioresistance and poor prognosis in
non-small-cell lung cancer (NSCLC) patients [176]. Moreover, cancer stem cells lose their ability to
repopulate the tumor after IR treatment when Notch activity is suppressed.
4.6. Hypoxia Pathway
The variety and severity of DNA damage from IR is influenced by the tumor microenvironment.
In particular, the molecular oxygen status of a tumor is known to influence the biological effect of
IR; cells become radioresistant under hypoxic conditions [177,178]. Many tumors comprise poorly
oxygenated hypoxic regions that are radioresistant and this depletion of oxygen results in inefficient
formation of DNA strand breaks by IR. Moreover, patients displaying highly hypoxic tumors have a
much poorer outcome than those with well-oxygenated tumors.
Hypoxia inducible factor 1 (HIF-1), the critical regulator of cellular responses to hypoxia, has
been shown to be involved in hypoxia-related tumor radioresistance [179–181]. HIF-1 modulates the
expression of over 100 genes involved in the regulation of proliferation, apoptosis, and angiogenesis.
HIF-1 expression levels increase under IR treatment as early as 24 h, and this effect persists
for up to one week. After irradiation, when radiosensitive cells are killed and they free up
oxygen to be delivered to the previously hypoxic regions, the hypoxic cells undergo reoxygenation.
The oxidative stress generated during reoxygenation causes activation of the HIF-1 pathway.
Therefore, paradoxically, reoxygenation causes activation of the HIF-1 pathway, which usually
responds to low oxygen levels. Due to its critical role in tumor radioresistance, HIF-1 may constitute
a therapeutic target for hypoxic tumors.
The interactions among hypoxia, angiogenesis, and radioresistance are well known.
Activation of the PI3K/Akt pathway, an important pathway involved in radioresistance, contributes
to the increased transcription and expression of HIF-1 [182]. VEGF, a major transcription target
of HIF-1 in hypoxic conditions, regulates various endothelial cell functions and induces tumor
neovascularization [183,184]. One of the important mechanisms by which inhibition of the
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epidermal growth factor receptor (EGFR) enhances tumor oxygenation is the regulation of VEGF.
Cooperation between the PTEN mutation and EGFR activation upregulates VEGF even under
normoxic conditions through the PI3K/Akt pathway. Tumor cell proliferation and angiogenesis,
which may be implicated in radioresistance, require the interaction between EGFR and VEGF and
downstream signaling of the PI3K/Akt pathway.
4.7. RTK-PI3K-Akt Pathway
In cancer cells, radiation-induced or constitutive signaling pathways that act through receptor
tyrosine kinases (RTKs) are implicated in modulating radioresistance. EGFR, an ErbB family member,
is a membrane-spanning tyrosine kinase receptor that plays an important role in regulating tumor
cell proliferation, survival, invasion, and angiogenesis. High-level EGFR expression is correlated
with radioresistance and poor outcome after radiotherapy in preclinical and clinical studies [185,186].
EGFR exerts prosurvival and pro-proliferation activities through the activation of downstream
signaling pathways, including the PI3K/Akt, STAT, and Ras–Raf–MAPK [187–189]. Among them,
the PI3K/Akt pathway is a key downstream survival pathway activated in cancer cells. The Akt
serine/threonine protein kinase, a central kinase downstream of PI3K, is involved in different aspects
of cellular regulation, such as cell growth, proliferation, survival, migration/invasion, metastasis,
angiogenesis, and metabolism.
Similar to ligand stimulation, IR stimulates EGFR signaling into its downstream
PI3K/Akt [190–192]. Hyperactive PI3K/Akt signaling is one of the factors responsible for the
development of cancer cells with increased resistance to radiotherapy. The role of PI3K/Akt
activity in radioresistance has been reported in various cancers, including those of the brain, lung,
colon, cervix, and head and neck. For example, constitutive phosphorylations of Akt, presumably
at Ser473 and Thr308, mediate radiotherapy resistance in NSCLC cells [193], and activation of
the PI3K/Akt/Cox-2 pathway enhances resistance to radiation in human cervical cancer [150].
RLIP76 can regulate PI3K/Akt signaling and induce radioresistance in pancreatic cancer, which
is an aggressive malignancy with characteristic resistance to conventional chemo-radiotherapy.
The function of the PI3K/Akt pathway in response to radiation is believed to be independent of
p53 status. Moreover, although PI3K activates other prosurvival effectors, such as SGK, Akt plays a
central role in PI3K-mediated radioresistance. Given that inhibition of Akt activity leads to impaired
DNA DSB repair following radiation and enhanced radiosensitivity, activation of Akt improves
post-irradiation cell survival by promoting the repair of IR-induced DNA DSBs, and might be of
particular importance in terms of radiotherapy outcome. Akt seems also to be involved in the
radioresistance of cancer stem cells through an as-yet-unknown mechanism.
Like apoptosis, autophagy has also been recognized as an important factor in determining the
response of tumor cells to radiotherapy. The PI3K/Akt signaling pathway is a major regulator
of autophagy [194,195]. Autophagy exhibits a biphasic effect against exposure of tumor cells to
IR, inducing a cytoprotective or cytotoxic effect [196,197]. The PI3K/Akt/mTOR pathway has
been implicated in the cytotoxic effect of radiation-induced autophagy. Akt inhibition exerts a
radiosensitizing effect in malignant glioma cells by inducing autophagy [198].
As mentioned above, two pathways are involved in DNA DSB repair: the NHEJ and HR
pathways. In the NHEJ repair pathway, Akt forms a functional complex with DNA-PKcs at the DNA
DSB site and stimulates DNA–PKcs kinase activity, all of which are necessary for the DNA DSB repair.
Akt-dependent phosphorylation/activation of DNA-PKcs indicates that Akt is involved in the first
initiating step of DNA DSB repair [199]. Akt can also be activated by the MRE11–RAD50–NBS1
(MRN)–ATM pathway as well as the PI3K pathway. The role of Akt in DSB repair is further
substantiated by radiation-induced colocalization of γH2AX foci and phosphorylated Akt in the site
of DSB [199–201]. BRCA1, BRCA2, and RAD51 are critical components of the HR repair pathway,
to which Akt activity is also linked. Particularly, whereas Akt stimulates the NHEJ pathway, its
aberrant activation suppresses the HR pathway and generates genetic instability in tumor cells [202].
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Because NHEJ is the predominant pathway in mammals, activation of the EGFR/PI3K/Akt signaling
pathway is crucial for tumor cell survival after radiation and the inhibition of Akt activity by
targeting the RTK–PI3K–Akt axis suppresses faithful repair of IR-induced DNA DSBs and improves
radiotherapy efficacy [203–206].
5. Strategies for Overcoming Resistance to IR
Radiation-induced apoptosis is a major cell death form in tumors derived from hematopoietic,
lymphoid, and germ cells. However, epithelial solid tumors show extensive resistance to IR-induced
apoptosis. Radioresistance is a serious concern, causing radiotherapy failure and subsequent tumor
relapse. Therefore, novel therapeutic radiosensitizers are urgently needed for overcoming tumor
radioresistance and thus improving the outcome of radiotherapy. A growing number of inhibitors
that target specific components of radioresistance pathways are being developed for clinical use.
Moreover, natural radiosensitizers have also been developed in an effort to compensate for the
limitations of synthetic inhibitors. Several strategies have been suggested for overcoming resistance
to IR in cancer treatment (Figure 4).
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5.1. Modifications in Fractionation
Fractionated radiation therapy for cancer has advantages over a single administration of
radiation because it can increase the anticancer therapeutic effect and decrease the occurrence of
severe side effects in normal tissues. In the most conventional fractionated radiation therapy, about
2.0 Gy of radiation is given per day, about 10 Gy per week, and up to about 60 Gy for six weeks in
total. Unfortunately, however, this strategy cannot sufficiently control locally advanced cancers and is
not satisfactory to patients due to its limited efficacy and the occurrence of side effects. New strategies
such as hypofractionation have been proposed to compensate for the limitations of conventional
fractionated radiation therapy. First, clinical trials are assessing the administration of larger doses
of radiotherapy per fraction in fewer fractions. Therefore, in the future, conventional radiotherapy
strategies will be replaced largely by hypofractionated radiation therapy, which delivers very potent,
focused beams of radiation to tumors but gives fewer radiation treatments. Hypofractionation
involves the delivery of daily doses larger than 2.0 Gy, shorter overall treatment times, and lower
overall doses. In this hypofractionated radiotherapy, although the dose of the single fraction is
higher, the total dose delivered is lower than in conventional radiotherapy. Hypofractionation
regimens take advantage of greater cell killing per fraction of the cell survival curve and combat
accelerated repopulation of tumor tissues. In particular, the use of hypofractionated radiation
treatment to specifically target brain tumors will be beneficial in terms of saving normal brain
tissue and preserving the brain’s various sub-functions (such as memory) compared to irradiating
the entire brain. Researchers are investigating various ways of giving standard external beam
radiotherapy, such as hyperfractionation and accelerated fractionation as well as hypofractionation.
In hyperfractionation, a smaller dose of radiation (e.g., ~1.2 Gy) is delivered twice per day with an
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interval of about 6 h, allowing the total dose of radiation to be increased, which has therapeutic
benefits and fewer side effects. In accelerated fractionation, a relatively high dose of radiation
(e.g., ~1.6 Gy) is applied twice per day but the total dose is identical to that used in conventional
radiotherapy. Because the total duration is shorter than that of conventional fractionation treatment,
this treatment strategy is advantageous, especially in very rapidly growing tumors.
5.2. Combined Treatment
In an effort to overcome tumor radioresistance, much research has focused on developing
tumor-specific radiosensitizers. Combined anticancer therapy has been emerging as an established
clinical practice. In many solid tumors, simultaneous treatment with chemotherapeutic agents and
radiation is far more effective than sequential single treatment. This is based on the principle that a
single chemotherapeutic or radiotherapeutic agent has low therapeutic activity in many tumor types,
whereas combining therapeutic agents with unrelated action mechanisms may result in synergistic,
or at least additive, anti-neoplastic effects.
5.2.1. Selective Molecularly Targeted Synthetic Agents
Hence, a variety of radiosensitizing agents have been developed to target DNA DSB repair
pathways, including small interfering RNAs, aptamers, antisense RNAs, and small-molecule
inhibitors, which are being clinically developed by a number of corporations. Various inhibitors of
Akt, mTOR, and Chk1/2 have been shown to act as potential radiosensitizers [198,203,207–212].
Because an intact or hyperactive HR is often correlated with radioresistance, exploring means
of inhibiting the HR repair pathway in cancer cells may be beneficial. A number of radiosensitizers
have been found to inhibit HR. Nucleoside and base analogs such as gemcitabine, TAS-106, gimeracil,
pentoxifylline, and caffeine are examples [127]. Furthermore, the ATR inhibitor VE-821 and the
Chk1/2 inhibitor AZD7762 have also been reported to inhibit HR [213,214]. The tyrosine kinase
inhibitors imatinib and erlotinib, the HDAC inhibitor PCI-24781, the proteasome inhibitor MG132,
and the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), all of which are less
directly implicated in the DNA damage signaling, are also suggested to radiosensitize cancer cells by
targeting the HR repair pathway [127].
Emerging evidence shows a novel role for radiotherapy as a therapeutic partner of cancer
immunotherapy. IR can act as an immune adjuvant, contributing to systemic antitumor immunity.
IR leads to the activation of several immunological proteins and transcription factors that modulate
the expression of numerous immune mediators that may promote cancer development. Thus, the
targeting of IR-induced inflammatory signaling pathways offers the opportunity to improve the
clinical outcomes of radiation therapy by enhancing radiosensitivity. Several studies have reported
the radiosensitizing effect of NF-κB inhibition in various models [215–217]. Clinical approaches
for NF-κB inhibition to induce tumor radiosensitization include corticosteroids, phytochemicals,
proteasome inhibitors, and synthetic peptides. The inhibition of Cox-2, one of the central enzymes
in the inflammatory response, using pharmacological inhibitors such as ascoxibs, celecoxib, and
SC-236, represents a radiosensitization strategy [142]. The combined treatment of radiation
and cisplatin might complement the intrinsic inability of this drug to induce redistribution of
calreticulin, a cisplatin-binding protein, thus affecting cell death. The combination of radiation
and the poly(ADP-ribose) polymerase inhibitor veliparib exerts its effect by promoting tumor
immunogenicity [218]. Preclinical studies have demonstrated that combining radiotherapy with
immune stimulation can induce antitumor immunity, enhancing cell death.
5.2.2. Radiosensitizers Derived from Natural Products
The clinical benefits of synthetic inhibitors in terms of improving treatment outcomes are
limited. In addition, the unintended and adverse side effects of these inhibitors are growing
concerns. These limitations prompt the development of novel and more effective radiosensitizers
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to address these unmet medical needs. Naturally occurring radiosensitizers are frequently believed
to be relatively safe compared to synthetic compounds because they are normally found in foods.
Moreover, natural products with antioxidant and immune-enhancing effects are believed to have
better biological and radioprotective effects for normal cells. Several natural radiosensitizers have
been reported (Table 1).
Curcumin
Curcumin, a polyphenol, is a natural compound derived from tumeric and curry
powders. Curcumin has various anticancer activities. It suppresses cancer cell proliferation,
downregulates NF-κB target genes, reduces the activity of growth factor receptors, and counteracts
tumorigenesis [219]. Interestingly, curcumin suppresses all three stages of carcinogenesis: initiation,
promotion, and progression. Resistance to radiation can be caused by increased expression of
NF-κB-induced prosurvival genes such as antiapoptotic Bcl-2 family members. Curcumin has
been shown to downregulate STAT3 phosphorylation as well as NF-κB expression induced by
various inflammatory stimuli [220]. Some studies show that curcumin sensitizes cancer cells to IR
through the inhibition of NF-κB activation [221,222]. Curcumin has also been reported to confer
protective effects against radiation-induced toxicity in normal cells/tissues through the activation
of Nrf2 antioxidant signaling pathways [222–224]. The fact that curcumin can achieve efficient
radiosensitizing effects without any toxicity makes its development as an adjunct to standard
radiotherapy an important goal.
Table 1. Effective natural radiosensitizers for the treatment of cancer. These compounds act as
radiosensitizers for cancer cells and, at the same time, radioprotectors for normal cells.
Name Types Source Radiosensitization Target inRadiosensitization Radioprotection
Target in
Radioprotection
Curcumin Polyphenol Tumeric Arrest, Apoptosis NF-kB Yes NRF2, Antioxidantenzymes
Resveratrol Polyphenol Grapes Apoptosis,Senescence NF-kB, Cox-2, 5-LOX Yes Not determined
Genistein Polyphenol Soybean Arrest, Apoptosis Akt, Erk, Survivin,Cycline B, NF-kB Yes Not determined
Quercetin Polyphenol Ubiquitous Arrest, Apoptosis ATM Yes Not determined
Resveratrol
Resveratrol is a polyphenol compound found in various dietary sources, including grapes,
wine, soy, berries, and peanuts. Resveratrol, a natural antioxidant, exerts an anticancer effect
by suppressing the proliferation of a variety of cancer cells. Resveratrol has been shown to
potentiate the apoptotic effects of IR as well as cytokines and chemotherapeutic agents [222,225,226].
Resveratrol induces radiosensitization through the inhibition of NF-κB, Cox-2, and 5-lipooxygenase
(5-LOX) [222]. Resveratrol also potentiates the IR-induced accumulation of ceramide, a potential
anticancer agent, by promoting its de novo biosynthesis [227]. Interestingly, resveratrol treatment
enhances IR-induced premature senescence rather than apoptosis in NSCLC [228].
In addition, chromosome aberration analyses in an irradiated mouse model support the use of
resveratrol as a radioprotector that has the potential for widespread application [229].
Genistein
Genistein is a naturally occurring soybean-derived isoflavone glycoside that inhibits protein
tyrosine kinase. Genistein can inhibit cancer cell growth by inducing apoptosis and differentiation
and/or by suppressing angiogenesis and metastasis. Anticancer effects of genistein are mediated
by the inhibition of protein tyrosine kinases, topoisomerase I/II, protein histidine kinases, and
the expression of cell cycle–related genes in multiple malignant tissues. Genistein in combination
with IR may enhance the efficacy of radiotherapy in numerous cancer cells by inhibiting DNA
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synthesis, cell division, and cell growth. For example, genistein greatly enhances the radiosensitivity
of human esophageal cancer cells by suppressing radiation-induced activation of survival signals
such as Akt and Erk [230]. Combination treatment with genistein and IR significantly induces G2/M
arrest followed by apoptosis by reducing the expression of survivin and cyclin B in cervical cancer
cells [231]. Genistein also increases radiation-induced apoptosis and promotes arrest at the G2 phase
of the cell cycle in leukemia cells [232]. Because cells in the G2/M phase are more sensitive to radiation
damage than those in other phases, G2/M arrest in response to genistein treatment can sensitize
cancer cells to IR-induced death. Combined treatment-induced G2/M arrest has been also reported in
other cancer cell types, such as prostate cancer cells [233]. In contrast, genistein can also protect from
IR-induced injury in human normal lymphocytes [234]. Moreover, the administration of genistein
alleviates the IR-induced injury in mice without adverse effects on motor activity, body weight, or
histopathology [224]. NF-κB inhibition mediated by genistein is also suggested to be an underlying
mechanism by which genistein exerts its anticancer and radiosensitizing effects. The increased cancer
cell death induced by the combined treatment of genistein and IR is assumed to occur largely via the
inhibition of NF-κB, leading to the decrease in cyclin B levels and/or the increase in the levels of the
cdk inhibitor p21, thus promoting G2/M arrest and increasing radiosensitivity.
Quercetin
Quercetin, one of the main components of flavonoids, is distributed ubiquitously in vegetables
and fruits such as apples, nuts, berries, onions, cauliflowers, and cabbages, and in red wine,
tea, and the propolis of honeybee hives. It has multiple effects on the immune system
and has been found to have antioxidant, antiviral, anti-inflammatory, and cardioprotective
activities. Quercetin has anticancer activity against several types of cancer by promoting apoptotic
cell death and inducing cell cycle arrest [235–237]. Quercetin also induces autophagy [236].
Its radiosensitizing activity has been demonstrated in various cancer cells and a human tumor
xenograft model [238]. Mechanistically, quercetin enhances tumor radiosensitization through
inhibition of the ATM-mediated pathway, one of the key DNA damage signaling pathways,
in response to radiation [238]. Quercetin exerts radioprotective and immunoprotective effects
against radiotherapy in normal tissue [239,240]. It also effectively protects lung tissue against
radiation-induced pulmonary injuries [240].
5.3. Modification of Inflammation
Recently, radiation oncologists came to pay attention to tumor stroma to increase the efficacy
of radiotherapy. Depletion of tumor-associated macrophages can increase the antitumor effects of
IR. For example, VEGF-neutralizing antibodies can enhance the antitumor response to IR through
downregulation of IR-induced VEGF in macrophages [241]. Immunestrategy exerts synergistic
antitumor activity with local radiation in preclinical studies. Since radiotherapy elicits in situ
vaccination, some novel approaches have tested radiotherapy in combination with cancer vaccines or
adoptive T-cell transfer [242]. Antibodies targeting immune checkpoint receptors and/or inducible
T-cell costimulatory receptors can also be successfully treated with radiotherapy [242].
5.4. Methods of Overcoming Tumor Hypoxia
Tumor hypoxia is considered one of major problems for radiation therapy because hypoxic
tumor cells are more likely to survive IR. To overcome tumor hypoxia, several therapeutic strategies
have been developed. The most common methods employed to overcome tumor hypoxia-related
resistance include radiation fractionation, the use of high linear energy transfer (LET) particles in the
management of hypoxic tumors, and the implementation of bioreductive drugs, such as adjuvant
treatment. Several methods of overcoming tumor hypoxia are outlined below.
First, the direct delivery of sufficient oxygen to locally advanced solid tumors during IR
treatment is one of the simplest and most effective options. Indeed, hyperbaric oxygenation, red
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blood cell transfusions, and erythropoietin administration have been investigated as methods of
increasing tumor oxygenation. Although these approaches showed therapeutic benefits in preclinical
studies, they are not in widespread use because of the conflicting results of clinical trials.
In the 1970s, nitroimidazole derivatives, such as misonidazole, were found to mimic the effect
of oxygen in the radiochemical process, raising the possibility of their use to enhance the cytotoxic
effect of IR under hypoxic conditions [181,243]. However, dose-limiting toxicities, mainly due to its
low solubility, led to a limited therapeutic benefit of misonidazole in clinical trials. Effective doses
of this drug were found to cause peripheral neuropathy, which has prevented its routine clinical use.
To solve this problem, other nitroimidazole derivatives with high solubility, such as etanidazole and
doranidazole, have been developed as promising candidates [181].
Because of its active role in the radioresistance of hypoxic tumor cells, HIF-1 has been recognized
as a prime molecular target for sensitization to the therapeutic effect of radiation. For example,
targeting tumor metabolism through HIF-1 inhibition enhances the radiation response in cervical
and head and neck xenograft tumors [244]. The well-known HIF-1 inhibitor YC-1 was found
to downregulate HIF-1α and HIF-2α through post-translational modifications and to inactivate
the carboxyl-terminal transactivation domain of HIF-1α [245]. It was also reported to decrease
HIF-1 target gene expression under hypoxic conditions, thereby inhibiting the growth and spread
of tumors [246,247]. Inhibition of the radiation-induced upregulation of HIF-1 activity by YC-1
dramatically suppresses tumor recurrence after radiotherapy [248]. Inhibition of the dimerization of
HIF-1α with HIF-1β also likely exerts a radiosensitizing effect because dimerization is a prerequisite
for DNA binding by, and transcriptional activity of, HIF-1 [249]. In this sense, acriflavine may
also be a potent HIF-1 inhibitor because it binds directly to HIF-1α and inhibits HIF-1 dimerization
and transcriptional activity [250]. However, the radiosensitizing activity of acriflavine has not been
examined to date. The negative regulation of key factors that upregulate the expression or activity
of HIF-1 represents another approach to HIF-1 inhibition. The PI3K-Akt-mTOR signaling pathway is
known to upregulate the expression of HIF-1α protein. Therefore, inhibitors of these pathways, such
as RAD-001, LY294002, wortmannin, and rapamycin, contribute to radiosensitization presumably by
suppressing HIF-1. HSP90 can also enhance HIF-1 expression; it binds to HIF-1α in competition with
RACK1 and inhibits the oxygen-independent degradation of HIF-1α [251]. Additionally, 17-AAG or
deguelin, a novel naturally occurring inhibitor of HSP90, suppresses an increase in the interaction
of HIF-1α with HSP90 in cancer cells [252]. Furthermore, combined treatment with IR and deguelin
significantly overcomes radioresistance in lung cancer cells [252].
A gene therapy strategy targeting hypoxic cancer cells would be also a good option for enhancing
radiosensitivity. A heterodimer with HIF-1α and HIF-1β binds directly to the hypoxia response
element (HRE) present in the promoter regions of target genes. HIF-1/HRE-mediated transcriptional
initiation has been suggested to facilitate induction of therapeutic gene expression in hypoxic regions
of solid tumors [181]. In particular, the targeted expression of apoptosis-related genes using the HRE
promoter in HIF-1-active malignant cancer cells will enable the resistance of hypoxic cells to IR to
be overcome.
Novel drugs, such as antiangiogenic/vascular targeting agents, that target genetically stable
vascular endothelial cells rather than unstable mutating tumor cells have been developed recently.
Tumor angiogenesis enables division of the primary cancer cells by adequately delivering
oxygen and nutrients, and targeting angiogenesis can enhance the efficacy of radiotherapy.
Considerable preclinical evidence suggests the efficacy of tumor radiosensitization in combination
with radiation and angiogenesis inhibition [253–255], and clinical trials of combinations of
angiogenesis inhibitors with radiotherapy are underway. Novel drugs that cause vascular
normalization or reduce tumor oxygen consumption will also be effective in terms of reducing
tumor hypoxia. Additionally, direct evidence shows that downregulation of prostaglandins by Cox-2
inhibitors results in a reduction of angiogenesis increasing radiosensitivity [256], confirming the
important role of angiogenesis in tumor radioresistance.
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6. Perspectives and Conclusions
Cancer is the global leading cause of disease and injury, the incidence of which will increase due
to the aging population. The number of patients receiving radiotherapy has been increasing steadily.
Radiotherapy can benefit patients for whom surgery is not possible by significantly shrinking or
destroying tumors. The exposure of tumors to IR triggers a variety of changes (either immediate
or persistent), ranging from mild biochemical changes to several forms of death. The total dose and
number of fractionation of IR can determine the degree and/or type of cellular damage. IR exerts
anti-cancer activity by eliciting multiple DNA lesions, such as DSBs, SSBs, DNA crosslinks, and
base modifications.
While radiation is effective against some types of tumors, other tumor types, such as pancreatic
carcinoma and glioblastoma multiforme, are intrinsically resistant to conventional radiation therapy,
making them more difficult to target. Several pathways determine the resistance of tumor cells
to IR. These include DNA repair pathways, developmental pathways, the adaptive response
pathway, adhesion pathways, the hypoxic pathway, and other survival pathways. Therefore, an
urgent clinical need exists to develop radiosensitizers to overcome tumor radioresistance and
thus enhance the effectiveness of radiotherapy. Combined chemotherapy and radiotherapy was
clinically successful in the treatment of many tumor types. Clinical trials are investigating drugs
that sensitize cancer cells to the effects of radiation, making them easier to destroy with radiation
therapy. Meanwhile, protective drugs may facilitate the recovery of normal and healthy cells after
exposure to radiation. Many current radiosensitization approaches target the DNA damage response.
Overall, however, the clinical outcomes of these attempts using targeted drugs as radiosensitizers
have generally remained disappointing. Therefore, novel radiosensitizing drugs should undergo
more extensive and careful preclinical studies before being introduced in the clinic by increasing
knowledge of their mechanisms of action.
To enhance the efficacy and cost-effectiveness of radiotherapy, the patient should also be
treated with radiotherapy that is more fine-tuned. Advances in technology and biology have led
to improvements in tumor delineation and targeting, resulting in improvement of tumor coverage
and a reduction in normal tissue exposure. Good examples of progress in radiotherapy are technical
advances such as image-guided radiotherapy (IGRT) and intensity-modulated radiation therapy
(IMRT), which target the tumor more accurately, sparing healthy normal tissue. These allow
physicians to shape radiotherapy very closely around a tumor from different directions, thereby
reducing the impact of high radiation doses on nearby healthy cells such as the spinal cord or
salivary glands, which, if damaged, would cause long-term problems. IMRT is a recently developed
powerful therapeutic strategy that enables radiation oncologists to precisely control the distribution
of radiation according to the overall shape of the tumor. Radiological imaging using computed
tomography (CT) and magnetic resonance imaging (MRI) and multileaf collimators can enhance
tumor specificity. With the help of these technologies, IMRT allows the delivery of precise radiation
doses to tumors without increasing the adverse effects on surrounding normal tissue. In particular,
simultaneous integrated boost IMRT (SIB-IMRT) enables the delivery of a booster dose of radiation
to tumor cells with high efficiency and accuracy.
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